Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | LIPC | P11150 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | LIPE | Q05469 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | ABHD16A | O95870 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2703046 | 1.00 | MGLL (0.57) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL2701500 | 0.87 | BCHE (0.62) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL2701849 | 0.87 | BCHE (0.62) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL2701389 | 0.86 | MGLL (0.53) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL2701805 | 0.86 | MGLL (0.53) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL2702372 | 0.85 | BCHE (0.78) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL2703048 | 0.85 | MGLL (0.54) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL2701647 | 0.85 | MGLL (0.54) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL2702514 | 0.85 | MGLL (0.60) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL2702203 | 0.85 | MGLL (0.54) | MGLLBCHELIPCACHELIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238131-A1 | 5-O-SUBSTITUTED 3-N-PHENYL-1,3,4-OXADIAZOLONES FOR MEDICAL USE | BIAL - Portela & Ca., S.A. (PT) | 2010-10-13 | — | — | EP | claimed |
| WO-2009084970-A1 | 5-O-SUBSTITUTED 3-N-PHENYL-1,3,4-OXADIAZOLONES FOR MEDICAL USE | BIAL-PORTELA & COMPANHIA, S.A. (PT) | 2009-07-09 | — | — | WO | claimed |
| EP-1480960-B1 | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, the production thereof and their use in medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-05-09 | — | — | EP | disclosed |
| US-6900233-B2 | Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-05-31 | — | — | US | disclosed |
| EP-1480960-A1 | SUBSTITUTED 3-PHENYL-5-ALKOXY-1,3,4-OXADIAZOL-2-ONES, THE PRODUCTION THEREOF AND THEIR USE IN MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2004-12-01 | — | — | EP | disclosed |
| US-20030181433-A1 | Substituted 3-phenyl-5-alkoxy-3H- (1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-09-25 | — | — | US | disclosed |
| WO-2003072555-A1 | SUBSTITUTED 3-PHENYL-5-ALKOXY-1,3,4-OXADIAZOL-2-ONES, THE PRODUCTION THEREOF AND THEIR USE IN MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181433-A1 | Substituted 3-phenyl-5-alkoxy-3H- (1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof | PNLIP, LIPC, LPL | MGLL 8/4885BCHE 343/4885LIPC 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.